Mingyan Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mingyan Jiang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Ju Gao
Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China
11 shared publications - Beibei Zhao
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 shared publications - Ben-Quan Qi
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 shared publications - Fang Liu
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 shared publications - Li Zhang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin China
10 shared publications - Li-Xian Chang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Figure S1. Swimming plot of all study participants Each bar represents an individual patient. Patients with ongoing response still being treated on protocol at the time of last follow-up are indicated with arrow.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Figure S1. Swimming plot of all study participants Each bar represents an individual patient. Patients with ongoing response still being treated on protocol at the time of last follow-up are indicated with arrow.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Figure S2. Overall Survival and Event-free Survival Outcome (A) Overall survival (OS) according to risk group. (B) Event-free survival (EFS) according to risk group. (C) OS stratified by following HSCT status. (D) EFS stratified by following HSCT status.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Figure S2. Overall Survival and Event-free Survival Outcome (A) Overall survival (OS) according to risk group. (B) Event-free survival (EFS) according to risk group. (C) OS stratified by following HSCT status. (D) EFS stratified by following HSCT status.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Table S1. Study Representativeness Table
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Table S1. Study Representativeness Table
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Table S2. Response outcomes of induction therapy
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Table S2. Response outcomes of induction therapy
- Open Access
- 22 June 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1844881
Baseline omega-3 nutritional status and supplementation response in pediatric attention-deficit/hyperactivity disorder: a systematic review and biomarker-stratified meta-analysis
Introduction: High heterogeneity characterizes the efficacy of omega-3 polyunsaturated fatty acid (PUFA) supplementation for attention-deficit/hyperactivity disorder (ADHD). This study aimed to examine whether baseline omega-3 nutritional status may partly explain variability in supplementation response. Methods: We conducted a PRISMA-compliant systematic review and meta-analysis registered in PROSPERO (CRD420251218861). PubMed, Embase, PsycINFO, and CENTRAL were searched from inception to December 2025. Eligible studies were randomized controlled trials (RCTs) of omega-3 supplementation in children and adolescents with ADHD that reported baseline nutritional biomarkers, such as erythrocyte EPA/DHA, and efficacy outcomes stratified or otherwise separable according to baseline biomarker status. Data were synthesized using random-effects meta-analysis of standardized mean differences (SMDs), with a prespecified categorical subgroup analysis comparing low-baseline versus normal/high or unstratified baseline estimates. Results: Seven RCTs, contributing 10 analytical estimates, were included. The overall pooled analysis showed a small statistically significant effect of omega-3 supplementation (SMD = 0.21, 95% CI: 0.04–0.38; p = 0.017), with moderate heterogeneity ( I 2 = 38.7%). Stratification by baseline biomarkers was associated with lower within-subgroup heterogeneity and suggested differential treatment effects by baseline status (χ 2 = 10.44, df = 1, p = 0.0012). The low-baseline subgroup (k = 4) showed a larger estimated effect (SMD = 0.52, 95% CI: 0.28–0.76; p < 0.001; I 2 = 0%), whereas the normal/high or unstratified baseline subgroup ( k = 6) did not show a statistically significant effect (SMD = 0.03, 95% CI: −0.15–0.21; p = 0.77; I 2 =). Discussion: Omega-3 supplementation response in pediatric ADHD may vary according to baseline nutritional status. However, the evidence base remains limited to seven RCTs, and definitions of low baseline status differed across trials according to biomarker matrix and study-specific thresholds. These findings should therefore be interpreted as preliminary and hypothesis-generating. Larger, prospectively stratified RCTs using harmonized biomarker assessments and standardized baseline cut-offs are needed before biomarker-guided omega-3 supplementation can be recommended for clinical nutritional guidance. Systematic review registration: PROSPERO https://www.crd.york.ac.uk/PROSPERO/view/CRD420251218861 , identifier CRD420251218861.
- 22 June 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1844881
Open AccessBaseline omega-3 nutritional status and supplementation response in pediatric attention-deficit/hyperactivity disorder: a systematic review and biomarker-stratified meta-analysis
Introduction: High heterogeneity characterizes the efficacy of omega-3 polyunsaturated fatty acid (PUFA) supplementation for attention-deficit/hyperactivity disorder (ADHD). This study aimed to examine whether baseline omega-3 nutritional status may partly explain variability in supplementation response. Methods: We conducted a PRISMA-compliant systematic review and meta-analysis registered in PROSPERO (CRD420251218861). PubMed, Embase, PsycINFO, and CENTRAL were searched from inception to December 2025. Eligible studies were randomized controlled trials (RCTs) of omega-3 supplementation in children and adolescents with ADHD that reported baseline nutritional biomarkers, such as erythrocyte EPA/DHA, and efficacy outcomes stratified or otherwise separable according to baseline biomarker status. Data were synthesized using random-effects meta-analysis of standardized mean differences (SMDs), with a prespecified categorical subgroup analysis comparing low-baseline versus normal/high or unstratified baseline estimates. Results: Seven RCTs, contributing 10 analytical estimates, were included. The overall pooled analysis showed a small statistically significant effect of omega-3 supplementation (SMD = 0.21, 95% CI: 0.04–0.38; p = 0.017), with moderate heterogeneity ( I 2 = 38.7%). Stratification by baseline biomarkers was associated with lower within-subgroup heterogeneity and suggested differential treatment effects by baseline status (χ 2 = 10.44, df = 1, p = 0.0012). The low-baseline subgroup (k = 4) showed a larger estimated effect (SMD = 0.52, 95% CI: 0.28–0.76; p < 0.001; I 2 = 0%), whereas the normal/high or unstratified baseline subgroup ( k = 6) did not show a statistically significant effect (SMD = 0.03, 95% CI: −0.15–0.21; p = 0.77; I 2 =). Discussion: Omega-3 supplementation response in pediatric ADHD may vary according to baseline nutritional status. However, the evidence base remains limited to seven RCTs, and definitions of low baseline status differed across trials according to biomarker matrix and study-specific thresholds. These findings should therefore be interpreted as preliminary and hypothesis-generating. Larger, prospectively stratified RCTs using harmonized biomarker assessments and standardized baseline cut-offs are needed before biomarker-guided omega-3 supplementation can be recommended for clinical nutritional guidance. Systematic review registration: PROSPERO https://www.crd.york.ac.uk/PROSPERO/view/CRD420251218861 , identifier CRD420251218861.
- Open Access
- 22 April 2026
- Published by Springer Nature in BMC Pediatrics
- Vol. 26 (1)
A novel mutation of IFT140 in a preschool child with Mainzer-Saldino syndrome accompanied by rare tumor blastic plasmacytoid dendritic cell neoplasm: a case report
Mainzer-Saldino syndrome is a rare autosomal recessive ciliopathy characterized by cone-shaped epiphyses, chronic renal failure, and early-onset severe ret
- 22 April 2026
- Published by Springer Nature in BMC Pediatrics
- Vol. 26 (1)
Open AccessA novel mutation of IFT140 in a preschool child with Mainzer-Saldino syndrome accompanied by rare tumor blastic plasmacytoid dendritic cell neoplasm: a case report
Mainzer-Saldino syndrome is a rare autosomal recessive ciliopathy characterized by cone-shaped epiphyses, chronic renal failure, and early-onset severe ret
- Open Access
- 10 February 2026
- Published by Springer Nature in neurogenetics
- Vol. 27 (1) , 13
A novel heterozygous mutation of BCL11B gene causes neurodevelopmental disorder and middle type hypospadias in a Chinese boy with 5 years follow-up
As a crucial transcription factor, BCL11 transcription factor B gene (BCL11B) is expressed in the cell nucleus, and also widely expressed in the nervous and immune systems. Function of BCL11B varied, mutation of BCL11B gene may involve diverse diseases, such as immunodeficiency 49 (IMD49) and intellectual developmental disorder with speech delay, dysmorphic facies, and T-cell abnormalities (IDDSFTA). Here we reported a Chinese boy with significant neurodevelopmental delay, whose genetic exam revealed the BCL11B gene mutation. During the 5-year follow-up, no serious immune system defects and infections were found, but some autism spectrum disorders gradually emerged, and the patient was finally diagnosed with IDDSFTA caused by BCL11B mutation. This study is the first to report the phenotypic association between BCL11B gene mutation and moderate hypospadias. Although a previous study has documented the co-occurrence of this gene mutation with hypospadias, the hypospadias in that case was of the mild form. The moderate phenotype presented in this case significantly expands the clinical spectrum of BCL11B-associated disorders.
- 10 February 2026
- Published by Springer Nature in neurogenetics
- Vol. 27 (1) , 13
Open AccessA novel heterozygous mutation of BCL11B gene causes neurodevelopmental disorder and middle type hypospadias in a Chinese boy with 5 years follow-up
As a crucial transcription factor, BCL11 transcription factor B gene (BCL11B) is expressed in the cell nucleus, and also widely expressed in the nervous and immune systems. Function of BCL11B varied, mutation of BCL11B gene may involve diverse diseases, such as immunodeficiency 49 (IMD49) and intellectual developmental disorder with speech delay, dysmorphic facies, and T-cell abnormalities (IDDSFTA). Here we reported a Chinese boy with significant neurodevelopmental delay, whose genetic exam revealed the BCL11B gene mutation. During the 5-year follow-up, no serious immune system defects and infections were found, but some autism spectrum disorders gradually emerged, and the patient was finally diagnosed with IDDSFTA caused by BCL11B mutation. This study is the first to report the phenotypic association between BCL11B gene mutation and moderate hypospadias. Although a previous study has documented the co-occurrence of this gene mutation with hypospadias, the hypospadias in that case was of the mild form. The moderate phenotype presented in this case significantly expands the clinical spectrum of BCL11B-associated disorders.
- Open Access
- 7 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (45) , e45583
Osteopetrosis misdiagnosed as congenital cytomegalovirus infection: A case report and literature review
Rationale: Infantile malignant osteopetrosis (IMO) (OMIM 259700) is a rare autosomal recessive disease that is caused by defective function of osteoclasts or a reduced number of osteoclasts, resulting in extensive bone sclerosis. The morbidity and mortality rates are extremely high. It may have similar clinical manifestations with congenital cytomegalovirus infection. Due to limited knowledge and heterogenous manifestations, clinical early diagnosis of the disease is challenging. Patient concerns: We reported a case of a 3-month, 15-day-old female child who presented with hematologic abnormalities, hepatosplenomegaly, and optic nerve abnormalities. The child was misdiagnosed congenital cytomegalovirus at the initial diagnosis. However, the child’s condition did not improve significantly after antiviral treatment. Fortunately, the child was then genetically tested for bone marrow failure disorders. Diagnoses: Infantile malignant osteopetrosis. Interventions: The treatment involved ganciclovir and transfusion of blood products. However, after 3 weeks of antiviral treatment, the child did not improve significantly. At that time, bone marrow failure disease and immunodeficiency disease gene test report suggested IMO. Her parents refused to do hematopoietic stem cell transplantation. Outcomes: Oral valganciclovir and transfusion of blood products treatment was continued. Lessons: Our report expands the understanding of IMO disease. It is important that patients with clinical features and hematologic findings similar to infection should undergo a thorough clinical evaluation and timely genetic analysis to identify the causative mutation to avoid delays in diagnosis and treatment.
- 7 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (45) , e45583
Open AccessOsteopetrosis misdiagnosed as congenital cytomegalovirus infection: A case report and literature review
Rationale: Infantile malignant osteopetrosis (IMO) (OMIM 259700) is a rare autosomal recessive disease that is caused by defective function of osteoclasts or a reduced number of osteoclasts, resulting in extensive bone sclerosis. The morbidity and mortality rates are extremely high. It may have similar clinical manifestations with congenital cytomegalovirus infection. Due to limited knowledge and heterogenous manifestations, clinical early diagnosis of the disease is challenging. Patient concerns: We reported a case of a 3-month, 15-day-old female child who presented with hematologic abnormalities, hepatosplenomegaly, and optic nerve abnormalities. The child was misdiagnosed congenital cytomegalovirus at the initial diagnosis. However, the child’s condition did not improve significantly after antiviral treatment. Fortunately, the child was then genetically tested for bone marrow failure disorders. Diagnoses: Infantile malignant osteopetrosis. Interventions: The treatment involved ganciclovir and transfusion of blood products. However, after 3 weeks of antiviral treatment, the child did not improve significantly. At that time, bone marrow failure disease and immunodeficiency disease gene test report suggested IMO. Her parents refused to do hematopoietic stem cell transplantation. Outcomes: Oral valganciclovir and transfusion of blood products treatment was continued. Lessons: Our report expands the understanding of IMO disease. It is important that patients with clinical features and hematologic findings similar to infection should undergo a thorough clinical evaluation and timely genetic analysis to identify the causative mutation to avoid delays in diagnosis and treatment.
- Open Access
- 29 September 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (10) , 5521-5530
Treatment of EPOR-rearranged acute lymphoblastic leukemia with ruxolitinib: case reports and review of the literature
Acute lymphoblastic leukemia (ALL) with erythropoietin receptor (EPOR) gene rearrangement is rarely reported. These patients test negative for the Philadelphia chromosome but exhibit a gene expression profile similar to that of Philadelphia chromosome-positive acute lymphoblastic leukemia, leading to their designation as Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL). EPOR-rearranged ALL exhibits aggressive clinical course and dismal prognosis with a short remission duration and high level of minimal residual disease (MRD). The addition of tyrosine kinase inhibitors or Janus kinases inhibitors to conventional chemotherapy is an effective treatment approach for patients with Ph-like ALL. Here, we present two pediatric cases of Ph-like ALL with EPOR rearrangement that were treated with ruxolitinib and provide a literature review to assess the effectiveness of this treatment.
- 29 September 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (10) , 5521-5530
Open AccessTreatment of EPOR-rearranged acute lymphoblastic leukemia with ruxolitinib: case reports and review of the literature
Acute lymphoblastic leukemia (ALL) with erythropoietin receptor (EPOR) gene rearrangement is rarely reported. These patients test negative for the Philadelphia chromosome but exhibit a gene expression profile similar to that of Philadelphia chromosome-positive acute lymphoblastic leukemia, leading to their designation as Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL). EPOR-rearranged ALL exhibits aggressive clinical course and dismal prognosis with a short remission duration and high level of minimal residual disease (MRD). The addition of tyrosine kinase inhibitors or Janus kinases inhibitors to conventional chemotherapy is an effective treatment approach for patients with Ph-like ALL. Here, we present two pediatric cases of Ph-like ALL with EPOR rearrangement that were treated with ruxolitinib and provide a literature review to assess the effectiveness of this treatment.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Figure S1. Swimming plot of all study participants Each bar represents an individual patient. Patients with ongoing response still being treated on protocol at the time of last follow-up are indicated with arrow.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Figure S1. Swimming plot of all study participants Each bar represents an individual patient. Patients with ongoing response still being treated on protocol at the time of last follow-up are indicated with arrow.